A retrospective cohort study of the time between prior antibiotics and checkpoint inhibitors and association with survival in melanoma patients

被引：0
作者：
Hirner, Jesse P. [1 ]
Rajeh, Ahmad [2 ]
Semenov, Yevgeniy R. [3 ,4 ]
Kwatra, Shawn G. [4 ]
Leboeuf, Nicole R. [2 ,5 ]
机构：
[1] Univ Nebraska Med Ctr, Dept Dermatol, Omaha, NE USA
[2] Harvard Med Sch, Boston, MA USA
[3] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA USA
[4] Johns Hopkins Univ, Dept Dermatol, Baltimore, MD USA
[5] Brigham & Womens Hosp, Dept Dermatol, Boston, MA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2025年 / 92卷 / 04期
关键词：
antibiotic; cancer; dysbiosis; gut microbiome; ICI; immune checkpoint inhibitor; immunooncology; immunotherapy; malignancy; melanoma; microbiome; microbiota; mortality; outcome; response; survival;
D O I：
10.1016/j.jaad.2024.10.083
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：878 / 879
页数：2
相关论文
共 50 条
  • [41] Can Delta Radiomics Improve the Prediction of Best Overall Response, Progression-Free Survival, and Overall Survival of Melanoma Patients Treated with Immune Checkpoint Inhibitors?
    Peisen, Felix
    Gerken, Annika
    Hering, Alessa
    Dahm, Isabel
    Nikolaou, Konstantin
    Gatidis, Sergios
    Eigentler, Thomas K.
    Amaral, Teresa
    Moltz, Jan H.
    Othman, Ahmed E.
    CANCERS, 2024, 16 (15)
  • [42] Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study
    Ravi, Vinod
    Subramaniam, Aparna
    Zheng, Jing
    Amini, Behrang
    Trinh, Van A.
    Joseph, Jocelyn
    Mennel, Robert G.
    Bishop, Andrew J.
    Sturgis, Erich M.
    Goepfert, Ryan P.
    Yalamanchili, Sudha
    Botello, Gilberto
    Stephen, Bettzy
    Piha-Paul, Sarina A.
    Patel, Anisha B.
    Lazar, Alexander J.
    Conley, Anthony P.
    Benjamin, Robert S.
    Patel, Shreyaskumar R.
    Futreal, Phillip A.
    Somaiah, Neeta
    Naing, Aung
    CANCER, 2022, 128 (18) : 3383 - 3391
  • [43] The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study
    Guven, Deniz Can
    Yekeduz, Emre
    Erul, Enes
    Yazgan, Sati Coskun
    Sahin, Taha Koray
    Karatas, Gokturk
    Aksoy, Sercan
    Erman, Mustafa
    Yalcin, Suayib
    Urun, Yuksel
    Kilickap, Saadettin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3599 - 3606
  • [44] Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma
    Paly, Victoria Federico
    Kurt, Murat
    Zhang, Lirong
    Butler, Marcus O.
    Michielin, Olivier
    Amadi, Adenike
    Hernlund, Emma
    Johnson, Helen M.
    Kotapati, Srividya
    Moshyk, Andriy
    Borrill, John
    MDM POLICY & PRACTICE, 2022, 7 (01)
  • [45] Novel use of immune checkpoint inhibitors for vaginal melanoma: A retrospective study
    Konishi, Kota
    Okamoto, Mamiko
    Yano, Mitsutake
    Nasu, Kaei
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2023, 156
  • [46] Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors
    Gaucher, Louis
    Adda, Leslie
    Sejourne, Alice
    Joachim, Camille
    Guillaume, Chaby
    Poulet, Claire
    Liabeuf, Sophie
    Gras-Champel, Valerie
    Masmoudi, Kamel
    Houessinon, Aline
    Bennis, Youssef
    Batteux, Benjamin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [47] Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: Retrospective single institutional study
    Nakamura, Yoshiyuki
    Fujisawa, Yasuhiro
    Tanaka, Ryota
    Maruyama, Hiroshi
    Ishitsuka, Yosuke
    Okiyama, Naoko
    Watanabe, Rei
    Fujimoto, Manabu
    JOURNAL OF DERMATOLOGY, 2018, 45 (11) : 1337 - 1339
  • [48] Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma
    Asdourian, Maria S.
    Otto, Tracey S.
    Jacoby, Ted V.
    Shah, Nishi
    Thompson, Leah L.
    Blum, Steven M.
    Reynolds, Kerry L.
    Semenov, Yevgeniy R.
    Lawrence, Donald P.
    Sullivan, Ryan J.
    Boland, Genevieve M.
    Villani, Alexandra-Chloe
    Chen, Steven T.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (05) : 1147 - 1149
  • [49] The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy
    Li, Manyu
    Zeng, Chaofan
    Yao, Jiannan
    Ge, Yang
    An, Guangyu
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 88
  • [50] Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study
    Lee, Ji Hyun
    Hyung, Sujin
    Lee, Jeeyun
    Choi, Sang-Hee
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (08)
12345